Show simple item record

dc.contributor.authorvan Rhee, F
dc.contributor.authorWong, R
dc.contributor.authorMunshi, N
dc.contributor.authorRossi, J
dc.contributor.authorKe, X
dc.contributor.authorFosså, A
dc.contributor.authorSimpson, D
dc.contributor.authorCapra, M
dc.contributor.authorLiu, T
dc.contributor.authorHsieh, R
dc.contributor.authorGoh, Y
dc.contributor.authorZhu, J
dc.contributor.authorCho, S
dc.contributor.authorRen, H
dc.contributor.authorCavet, James
dc.contributor.authorBandekar, R
dc.contributor.authorRothman, M
dc.contributor.authorPuchalski, T
dc.contributor.authorReddy, M
dc.contributor.authorvan de Velde, H
dc.contributor.authorVermeulen, J
dc.contributor.authorCasper, C
dc.date.accessioned2014-09-04T09:11:36Z
dc.date.available2014-09-04T09:11:36Z
dc.date.issued2014-08
dc.identifier.citationSiltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. 2014, 15 (9):966-74 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid25042199
dc.identifier.doi10.1016/S1470-2045(14)70319-5
dc.identifier.urihttp://hdl.handle.net/10541/325867
dc.description.abstractMulticentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and efficacy of siltuximab-a chimeric monoclonal antibody against interleukin 6-in HIV-negative patients with multicentric Castleman's disease.
dc.language.isoenen
dc.rightsArchived with thanks to The lancet oncologyen
dc.titleSiltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.en
dc.typeArticleen
dc.contributor.departmentMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.en
dc.identifier.journalThe Lancet Oncologyen
html.description.abstractMulticentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and efficacy of siltuximab-a chimeric monoclonal antibody against interleukin 6-in HIV-negative patients with multicentric Castleman's disease.


Files in this item

This item appears in the following Collection(s)

Show simple item record